United Therapeutics Corporation $UTHR Position Raised by Augustine Asset Management Inc.

Augustine Asset Management Inc. grew its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 22.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,488 shares of the biotechnology company’s stock after buying an additional 1,206 shares during the period. United Therapeutics accounts for about 0.5% of Augustine Asset Management Inc.’s investment portfolio, making the stock its 27th biggest holding. Augustine Asset Management Inc.’s holdings in United Therapeutics were worth $2,720,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Chung Wu Investment Group LLC acquired a new position in United Therapeutics during the second quarter worth about $29,000. WealthCollab LLC boosted its holdings in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. increased its stake in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the last quarter. Geneos Wealth Management Inc. lifted its holdings in shares of United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares during the last quarter. Finally, True Wealth Design LLC grew its position in United Therapeutics by 738.5% in the third quarter. True Wealth Design LLC now owns 109 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 96 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $489.69 on Tuesday. The company has a market capitalization of $21.09 billion, a P/E ratio of 18.56, a price-to-earnings-growth ratio of 4.77 and a beta of 0.84. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $519.99. The company’s 50 day moving average price is $479.72 and its two-hundred day moving average price is $397.27.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.89 by $0.27. The firm had revenue of $799.50 million for the quarter, compared to the consensus estimate of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The company’s revenue for the quarter was up 6.8% on a year-over-year basis. During the same quarter last year, the business posted $6.39 EPS. Analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on UTHR. Morgan Stanley set a $447.00 target price on United Therapeutics in a research report on Wednesday, October 29th. Jefferies Financial Group restated a “buy” rating and issued a $575.00 price objective on shares of United Therapeutics in a research note on Wednesday, November 19th. HC Wainwright increased their price objective on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Cantor Fitzgerald increased their price target on United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 10th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $505.00.

Insider Buying and Selling at United Therapeutics

In related news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction dated Monday, October 27th. The stock was sold at an average price of $417.50, for a total transaction of $9,393,750.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last three months, insiders sold 592,964 shares of company stock valued at $276,457,860. 10.30% of the stock is owned by company insiders.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.